Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/17/2025

Calcium Administration in Kidney Disease

Dosing and Administration

  • Administer calcium gluconate through a central venous catheter whenever possible to prevent severe skin and soft tissue injury from extravasation 1, 2
  • Infuse calcium gluconate over 30-60 minutes for most indications 1, 2
  • For symptomatic hypocalcemia requiring immediate intervention, administer 50-100 mg/kg as a slow infusion with continuous ECG monitoring 1, 2

Critical Precautions

  • Exercise extreme caution when administering calcium gluconate to patients with hyperphosphatemia due to risk of calcium-phosphate precipitation in tissues and consequential obstructive uropathy 1
  • In CKD G3a-G5D, restrict the dose of calcium-based phosphate binders, particularly in the presence of arterial calcification, adynamic bone disease, or persistently low PTH levels 3

Hemodialysis Considerations

  • Use a dialysate calcium concentration between 1.25 and 1.50 mmol/L (2.5 and 3.0 mEq/L) in patients with CKD G5D 3
  • For CKD patients post-parathyroidectomy, if ionized calcium falls below normal, initiate calcium gluconate infusion at 1-2 mg elemental calcium per kg body weight per hour 4

Monitoring Requirements

  • Monitor ionized calcium levels regularly during infusion to avoid severe hypercalcemia (ionized calcium >2× upper limit of normal) 2
  • Maintain serum calcium in the normal range while avoiding hypercalcemia 3
  • Continuous ECG monitoring is essential during calcium administration, especially in patients with hyperkalemia or QT prolongation 1, 2

Elemental Calcium Content

  • One 10-mL ampule of 10% calcium gluconate contains 90-93 mg of elemental calcium 4
  • Calcium gluconate is preferred in CKD as it has a lower elemental calcium content compared to calcium chloride, which increases risk of metabolic acidosis 4

Common Pitfalls to Avoid

  • Do not use calcium carbonate as a phosphate binder in patients with elevated calcium levels 1
  • Do not routinely discontinue RAAS antagonists in CKD patients during calcium administration, but temporarily suspend during acute illness 5

REFERENCES